Overview
McDermott Will & Emery has advised TreeFrog Therapeutics, a French biotech company aiming to unlock access to cell therapies for millions of patients, on a licensing agreement and collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), an international biotech laboratory specializing in the scientific research and development of innovative drugs for severe diseases.
As part of this transaction, Vertex has obtained an exclusive license to TreeFrog’s patented cell manufacturing technology, C-StemTM, to optimize the production of Vertex’s cell-based therapies for type 1 diabetes (T1D). TreeFrog and Vertex will collaborate to develop TreeFrog’s process for producing and amplifying cells for Vertex’s type 1 diabetes therapies.
The McDermott team advising TreeFrog Therapeutics included:
- Rich B. Smith, counsel in Boston, Emmanuelle Trombe, partner and Katya Ascher, counsel in healthcare law and Edouard Becker.
- Other members of the team were Sabine Nauges, partner, on regulatory aspects, and Côme de Saint Vincent, counsel, on tax law.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
